Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 20,694 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: selumetinib, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 3 more

Conditions: B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions: nilotinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, methotrexate, cytarabine, prednisone, mesna, dexamethasone, leucovorin calcium; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Measurement of drug (Adalimumab/Infliximab), Intensify treatment with the existing drug; Other
Lead sponsor: University of Western Ontario, Canada; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • San Francisco, California • New Haven, Connecticut + 19 more

Conditions: Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Durvalumab, Tremelimumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Prevention
Interventions: C4 Program, C4 + 3MV Program; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Liver Transplant Rejection
Interventions: Liver Transplant; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Newly Diagnosed High-Grade Gliomas, Diffuse Intrinsic Pontine Glioma
Interventions: Temozolomide, Bevacizumab, Irinotecan; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 30 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Cincinnati, Ohio

Conditions: Colorectal Cancer
Interventions: Capecitabine and Cetuximab; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions: Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 213
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 90
States / cities: Dublin, California • Fremont, California • Fresno, California + 69 more

Conditions: Fanconi Anemia
Interventions: CD34+ selected cells; Biological
Lead sponsor: Neena Kapoor, M.D.; Other
Eligibility: 8 Weeks to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Magnetic Resonance Imaging, Neurodevelopmental Testing; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: BMS-214662, trastuzumab, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Type 1 Diabetes
Interventions: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COVID-19
Interventions: Duvelisib, Peripheral blood draw, Placebo; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Brain and Central Nervous System Tumors
Interventions: aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgery; Biological · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1999
U.S. locations: 3
States / cities: Denver, Colorado

Conditions: Diabetes Mellitus, Hyperglycemia
Interventions: Closed-loop blood glucose control; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions: Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 26
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 21 more

Conditions: Primary Immunodeficiency
Interventions: Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%; Biological
Lead sponsor: Prometic Biotherapeutics, Inc.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 13
States / cities: Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more

Conditions: Brain Concussion, Post-Concussion Syndrome
Interventions: Not listed
Lead sponsor: Southern Methodist University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 62
States / cities: Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more

Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Interventions: Conditioning Chemotherapy, Cord blood graft; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Evaluation of Health Costs and Resource Utilization

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM

The TOGETHER Project - Liver

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Unrelated HSCT in Patients With Fanconi Anemia

Cerebral Anatomy, Hemodynamics and Metabolism

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

Duvelisib to Combat COVID-19

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

Inpatient Closed-loop Glucose Control

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Cerebral Blood Flow Regulation and Concussions

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Cord Blood Transplant in Adults With Blood Cancers